We are live on ! Find out more
DFTX

Definium Therapeutics

159 hedge funds and large institutions have $53.6M invested in Definium Therapeutics in 2022 Q1 according to their latest regulatory filings, with 32 funds opening new positions, 33 increasing their positions, 41 reducing their positions, and 48 closing their positions.

New
Increased
Maintained
Reduced
Closed

180% more call options, than puts

Call options by funds: $4.31M | Put options by funds: $1.54M

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

0.06% less ownership

Funds ownership: 0.82%0.76% (-0.06%)

10% less funds holding

Funds holding: 176159 (-17)

20% less repeat investments, than reductions

Existing positions increased: 33 | Existing positions reduced: 41

26% less capital invested

Capital invested by funds: $72.4M → $53.6M (-$18.9M)

33% less first-time investments, than exits

New positions opened: 32 | Existing positions closed: 48

Holders
159
Holders Change
-17
Holders Change %
-9.66%
% of All Funds
2.51%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
32
Increased
33
Reduced
41
Closed
48
Calls
$4.31M
Puts
$1.54M
Net Calls
+$2.77M
Net Calls Change
-$81K
Name Holding Trade Value Shares
Change
Change in
Stake
BlackRock
1
BlackRock
New York
$18.2M -$730K -42,091 -4%
State Street
2
State Street
Massachusetts
$6.82M +$482K +27,784 +7%
Geode Capital Management
3
Geode Capital Management
Massachusetts
$3.13M -$99.5K -5,737 -3%
Northern Trust
4
Northern Trust
Illinois
$2.52M -$309K -17,812 -11%
Morgan Stanley
5
Morgan Stanley
New York
$2.19M -$492K -28,372 -18%
Vanguard Group
6
Vanguard Group
Pennsylvania
$2.11M -$83.1K -4,790 -4%
DCI
7
Data Collective IV
California
$1.67M
BB
8
Busey Bank
Illinois
$1.39M
Citadel Advisors
9
Citadel Advisors
Florida
$1.33M -$533K -30,712 -28%
Swiss National Bank
10
Swiss National Bank
Switzerland
$1.08M +$206K +11,887 +23%
Bank of New York Mellon
11
Bank of New York Mellon
New York
$1.04M +$19.4K +1,117 +2%
Charles Schwab
12
Charles Schwab
California
$798K -$35.7K -2,055 -4%
Susquehanna International Group
13
Susquehanna International Group
Pennsylvania
$759K -$428K -24,659 -35%
Two Sigma Investments
14
Two Sigma Investments
New York
$752K -$516K -29,733 -40%
AI
15
AdvisorShares Investments
Maryland
$721K +$268K +15,443 +55%
Group One Trading
16
Group One Trading
Illinois
$594K +$68.6K +3,956 +12%
Millennium Management
17
Millennium Management
New York
$484K -$740K -42,655 -59%
PCM
18
Penserra Capital Management
California
$442K +$276K +15,916 +99%
Deutsche Bank
19
Deutsche Bank
Germany
$406K +$40K +2,304 +10%
Goldman Sachs
20
Goldman Sachs
New York
$386K +$138K +7,938 +52%
Jane Street
21
Jane Street
New York
$338K +$142K +8,173 +70%
RhumbLine Advisers
22
RhumbLine Advisers
Massachusetts
$335K -$9.56K -551 -3%
AllianceBernstein
23
AllianceBernstein
Tennessee
$324K +$1.27K +73 +0.4%
CS
24
Credit Suisse
Switzerland
$309K +$74K +4,265 +30%
MI
25
MMCAP International
Cayman Islands
$267K +$278K +16,020 New

DFTX Hedge Fund Activity: Q1 2022 in Review

159 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Definium Therapeutics (DFTX) for Q1 2022, worth a combined $53.6M — down 26% from $72.4M a quarter earlier.

Sellers outnumbered buyers: 48 funds closed out of DFTX and 32 opened new positions — a net loss of 16 holders — while 41 trimmed existing stakes and 33 added.

The largest buyer was State Street, adding an estimated $482K. The largest seller was Millennium Management, cutting an estimated $740K.

  • 159 institutional investors held Definium Therapeutics (DFTX) as of Q1 2022, down from 176 in Q4 2021.
  • Funds reported $53.6M of Definium Therapeutics stock for Q1 2022, down 26% quarter-over-quarter.
  • 32 funds opened new Definium Therapeutics positions in Q1 2022 and 48 closed out, a net change of -16 holders.
  • The largest Definium Therapeutics buyer in Q1 2022 was State Street, an estimated $482K added.
  • The largest Definium Therapeutics seller in Q1 2022 was Millennium Management, an estimated $740K sold.

Based on aggregated 13F filings for Q1 2022.